Compugen Ltd. (NASDAQ:CGEN) Receives Consensus Recommendation of “Buy” from Analysts

Compugen Ltd. (NASDAQ:CGEN) has earned an average rating of “Buy” from the five analysts that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $5.00.

A number of equities analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Compugen in a research report on Tuesday, August 4th. Leerink Partners lowered their target price on Compugen from $13.00 to $5.00 and set an “outperform” rating for the company in a report on Thursday, May 21st. Weiss Ratings raised Compugen from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Finally, Wall Street Zen lowered Compugen from a “buy” rating to a “hold” rating in a research note on Saturday, May 23rd.

Institutional Investors Weigh In On Compugen

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Franklin Resources Inc. purchased a new stake in shares of Compugen in the second quarter valued at approximately $56,000. Jane Street Group LLC increased its stake in shares of Compugen by 1,077.0% during the second quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock worth $700,000 after purchasing an additional 359,785 shares in the last quarter. Osaic Holdings Inc. raised its holdings in shares of Compugen by 346.0% during the second quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 34,045 shares during the last quarter. Two Sigma Investments LP grew its holdings in shares of Compugen by 10.6% during the third quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock worth $291,000 after buying an additional 18,929 shares in the last quarter. Finally, Raymond James Financial Inc. lifted its stake in shares of Compugen by 51.0% in the third quarter. Raymond James Financial Inc. now owns 101,256 shares of the biotechnology company’s stock worth $149,000 after buying an additional 34,215 shares in the last quarter. 12.22% of the stock is currently owned by institutional investors and hedge funds.

Compugen Trading Down 2.9%

Shares of CGEN opened at $2.34 on Tuesday. The firm has a fifty day moving average price of $2.23 and a 200-day moving average price of $2.27. The firm has a market capitalization of $221.25 million, a P/E ratio of 6.16 and a beta of 2.77. Compugen has a 12-month low of $1.29 and a 12-month high of $3.23.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings results on Monday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. The company had revenue of $2.60 million for the quarter, compared to the consensus estimate of $1.28 million. Compugen had a net margin of 47.56% and a return on equity of 42.57%. During the same quarter last year, the firm posted ($0.08) EPS. Analysts predict that Compugen will post -0.27 earnings per share for the current year.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.